Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
95Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $64.93B | $18.25B | $7.30 |
| 2024 | $64.17B | $17.12B | $6.76 |
| 2023 | $60.12B | $365.00M | $0.14 |
| 2022 | $59.28B | $14.52B | $5.73 |
| 2021 | $48.70B | $13.05B | $5.16 |
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $2.22 per share
Typical surprise +4.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.13 vs $-0.27beat
- Thu, Apr 30$-1.28 vs $-1.47beat
- Tue, Feb 3$2.04 vs $2.01beat
- Thu, Oct 30$2.58 vs $2.36beat
- Tue, Jul 29$2.13 vs $2.03beat
- Thu, Apr 24$2.22 vs $2.13beat
Estimates and results for MRK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MRK's reported EPS growth of 9.1% a year over 4 years.
- EPS in 5 years
- $11.28
- Implied price
- $157.88
- Return from $135.84
- 3.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $78.49 — -42.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| -0.9% | -12.5% | -9.2% | -6.4% | -3.9% | -1.6% |
| 4.1% | -8.1% | -4.7% | -1.7% | 1.0% | 3.4% |
| 9.1% | -3.7% | -0.1% | 3.1% | 5.8% | 8.4% |
| 14.1% | 0.8% | 4.5% | 7.8% | 10.7% | 13.3% |
| 19.1% | 5.2% | 9.1% | 12.5% | 15.5% | 18.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (4)
- Newszacks.com·2d ago·Neutral
Can Keytruda Sustain Merck's Growth in the Second Half of 2026? MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.
View source ↗ - 4chan /biz/biz·2d ago·Positive
Do you know about the HALO trade? Heavy Assets Low Obsolescence HALO It's become basically the counter AI trade. HALO companies are companies with high capital costs, and heavy assets. And big moats. Like a manufacturing company, like Ford or some shit, or Walmart. It's had a low correlation with the AI trade. There's some new HALO etfs, but they have like 70 bps fees or some shit. I'll show you a HALO ETF with dirt cheap fees. SCHD. It's not a perfect HALO tracker but it's like 90% there. A
View source ↗ - Newszacks.com·4d ago·Neutral
MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell? Merck's strong Keytruda sales and pipeline progress support its long-term outlook, but falling estimates and patent risks cloud the near term.
View source ↗ - News (RSS)cnbc·11d ago·Negative
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
View source ↗